01—Abstract
Summary
Summary of the 8-K filed October 21, 2026. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. reported third quarter 2026 results on October 21, 2026, as furnished under Item 2.02 with the press release attached as Exhibit 99.1.
Revenue for the quarter was $716.0 milliona, up 8.5% from $659.9 million a year earlier, and the backlog conversion rate was 23.8%. Net new business awards were $873.4 million, up 10.6% from $789.6 million. GAAP net income was $137.5 million, or $4.84 per diluted share, versus $111.1 million, or $3.86 per diluted share, in the prior-year quarter.
EBITDA was $172.1 millionb, up 16.0%, with an EBITDA margin of 24.0%. Backlog as of September 30, 2026 was $3,167.2 million, up 5.6%. For the nine months ended September 30, 2026, revenue was $2,129.9 million, up 16.9% on a reported basis, and GAAP net income was $382.7 million, or $13.37 per diluted share.
The company forecasts 2026 revenue of $2.835 billion to $2.855 billionc, GAAP net income of $514.0 million to $524.0 million, and diluted EPS of $17.97 to $18.32. Guidance excludes any share repurchases made after September 30, 2026. Under Item 8.01, the Board terminated the existing repurchase authorization, which had $527.0 million remaining and was set to expire December 31, 2026, effective October 20, 2026, and approved a new authorization of up to $1.0 billion of common stock through December 31, 2028.
Repurchases are to be funded from cash on hand, and the authorization may be modified or terminated at any time. The company reported cash and cash equivalents of $705.3 milliond at September 30, 2026, and no share repurchases in the third quarter.
02—Key points
Key Highlights
- Q3 2026 revenue of $716.0 million rose 8.5% year over year; constant-currency growth was 8.6%.
- Q3 2026 net new business awards of $873.4 million rose 10.6%, and backlog reached $3,167.2 million, up 5.6%.
- Q3 2026 GAAP diluted EPS was $4.84 versus $3.86 a year earlier; EBITDA was $172.1 million, up 16.0%, at a 24.0% margin.
- Nine-month 2026 revenue was $2,129.9 million, up 16.9% on a reported basis, and GAAP diluted EPS was $13.37 versus $10.64.
- 2026 guidance calls for revenue of $2.835 billion to $2.855 billion, GAAP net income of $514.0 million to $524.0 million, and diluted EPS of $17.97 to $18.32.
- The Board terminated the prior repurchase authorization (with $527.0 million remaining) and approved a new authorization of up to $1.0 billion through December 31, 2028, funded from cash on hand.
- Cash and cash equivalents were $705.3 million at September 30, 2026, and no shares were repurchased in Q3 2026.
03—Questions
Frequently Asked Questions
How did Medpace perform in the third quarter of 2026?
Revenue rose 8.5% to $716.0 million, GAAP net income was $137.5 million ($4.84 per diluted share), and EBITDA increased 16.0% to $172.1 million, a 24.0% margin. Net new business awards grew 10.6% to $873.4 million.
What is the company's 2026 outlook?
Medpace forecasts 2026 revenue of $2.835 billion to $2.855 billion, GAAP net income of $514.0 million to $524.0 million, EBITDA of $638.0 million to $652.0 million, and diluted EPS of $17.97 to $18.32. The guidance assumes a tax rate of 19.0% to 19.5% and 28.6 million diluted weighted average shares, and it does not include any share repurchases after September 30, 2026.
What changed with the share repurchase program?
Effective October 20, 2026, the Board terminated the existing authorization, which had $527.0 million remaining and was set to expire December 31, 2026, and approved a new authorization of up to $1.0 billion of common stock through December 31, 2028. Repurchases may be made through open market, privately negotiated, Rule 10b5-1, or other transactions, funded from cash on hand, and the program may be modified or terminated at any time without notice.
How strong is the company's backlog and new business pipeline?
Backlog as of September 30, 2026 was $3,167.2 million, up 5.6% from $3,000.6 million a year earlier. Net new business awards for the quarter were $873.4 million, up 10.6% from $789.6 million, and the backlog conversion rate for the quarter was 23.8%.
What was the company's liquidity position at quarter end?
Cash and cash equivalents were $705.3 million at September 30, 2026, up from $497.0 million at December 31, 2025. Operating cash flow was $216.6 million in the third quarter and $530.4 million for the nine months. The company made no share repurchases in the third quarter.
04—Continue